EXOZYMES Business Summary

EXOZYMES INC. (NASDAQ: EXOZ), formerly Invizyne Technologies, operates a proprietary "platform-of-platforms" business model centered on AI-engineered, cell-free enzyme cascades for biomanufacturing. The company generates revenue through a mix of technology licensing, joint ventures, and strategic partnerships, targeting high-margin segments in the pharmaceutical, nutraceutical, and specialty chemical markets. Its core technology, SimplePath, bypasses the scaling limitations of traditional cell-based synthetic biology by utilizing optimized enzymatic pathways to convert sustainable feedstocks into complex molecules like N-acetyl-neuraminic acid (NCT) and Santalene. Positioned as a pioneer in the cell-free revolution, EXOZ competes directly with industrial enzyme leaders and synthetic biology firms such as Codexis, Inc., Ginkgo Bioworks, and Dyadic International, differentiating itself by offering a more modular and predictable production alternative to conventional fermentation. The company’s leadership is anchored by a blend of scientific founders and seasoned commercial executives. Michael Heltzen serves as Chief Executive Officer and President, bringing extensive experience in scaling biotech ventures, while co-founder Dr. Tyler Korman serves as Chief Scientific Officer, having pioneered the company’s underlying technology during his tenure at UCLA. The executive team also includes Chief Commercial Officer Damien Perriman and co-founder Dr. Paul Opgenorth, VP of Product Development. EXOZ is heavily backed by MDB Capital Holdings, with MDB CEO Christopher Marlett serving as Chairman of the Board. The board further benefits from the expertise of Dr. James Bowie, a UCLA Professor Emeritus and co-founder, and Dr. Jim Lalonde, formerly the Senior Vice President of R&D at Codexis, providing the company with deep technical and strategic pedigree in the biocatalysis sector.